In Spain, approximately 3.4 million people live with a rare disease. For many of them, therapeutic innovation may be the only available option. Orphan drugs are those intended to prevent, diagnose, or treat rare diseases, but their development presents specific challenges stemming from the small number of patients, the limited availability of evidence, and the high unmet medical need.

In light of the upcoming election and the process of drafting the platforms of the major political parties, the Spanish Association of Orphan and Ultra-Orphan Drug Laboratories (AELMHU) has presented ten priorities for the next legislative term, calling for a cross-cutting commitment to rare diseases and their treatments—one that encompasses not only health policies but also industrial, scientific, economic, and competitiveness policies.

Access the full press release here.